JP2000500124A - ウイルス、腫瘍、細菌および寄生体の抑制において免疫応答を特に調節するための医薬 - Google Patents
ウイルス、腫瘍、細菌および寄生体の抑制において免疫応答を特に調節するための医薬Info
- Publication number
- JP2000500124A JP2000500124A JP9517831A JP51783197A JP2000500124A JP 2000500124 A JP2000500124 A JP 2000500124A JP 9517831 A JP9517831 A JP 9517831A JP 51783197 A JP51783197 A JP 51783197A JP 2000500124 A JP2000500124 A JP 2000500124A
- Authority
- JP
- Japan
- Prior art keywords
- annexin
- phosphatidylserine
- active compound
- use according
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ウイルス、腫瘍、細菌および寄生体の抑制において免疫応答を特に調節する ための医薬であって、 アネキシン、アネキシン抗体、アネキシンリガンド、ホスファチジルセリンま たはホスホジエステラーゼからなる群より選択される活性化合物を、ホスファチ ジルセリン依存性の食作用に影響を及ぼすために含有することを特徴とする、医 薬。 2.前記アネキシンがV型のアネキシンであることを特徴とする、請求項1に記 載の医薬。 3.前記アネキシン抗体が抗アネキシンV抗体であることを特徴とする、請求項 1に記載の医薬。 4.前記アネキシンが融合タンパク質の構成成分であることを特徴とする、請求 項1または2に記載の医薬。 5.前記融合タンパク質が、ポリオウイルスから好ましくは誘導されるRNAベ クターに結合されることを特徴とする、請求項4に記載の医薬。 6.ウイルス、腫瘍、細菌および寄生体の抑制において免疫応答を特に調節する ための医薬の製造のための活性化合物の使用であって、 前記活性化合物が、ホスファチジルセリン依存性の食作用に影響を及ぼすため 、アネキシン、アネキシン抗体、アネキシンリガンド、ホスファチジルセリンま たはホスホジエステラーゼからなる群より選択されることを特徴とする、活性化 合物の使用。 7.前記アネキシンがV型のアネキシンであることを特徴とする、請求項6に記 載の使用。 8.前記アネキシン抗体が抗アネキシンV抗体であることを特徴とする、請求項 6に記載の使用。 9.前記アネキシンが融合タンパク質の構成成分であることを特徴とする、請求 項6または7に記載の使用。 10.前記融合タンパク質が、ポリオウイルスから好ましくは誘導されるRNA ベクターに結合されることを特徴とする、請求項9に記載の使用。 11.前記活性化合物により生じる作用は、ホスファチジルセリン依存性食作用 の遮断であることを特徴とする、請求項6〜10のいずれか1項に記載の使用。 12.前記活性化合物により生じる作用は、ホスファチジルセリン依存性食作用 の刺激であることを特徴とする、請求項6〜11のいずれか1項に記載の使用。 13.細胞外膜上に局在するホスファチジルセリンの、遮断および/または遮蔽 および/またはマスキングおよび/または除去によって、免疫刺激がもたらされ ることを特徴とする、請求項11に記載の使用。 14.前記活性化合物が免疫応答の調節剤として用いられることを特徴とする、 請求項6〜13のいずれか1項に記載の使用。 15.腫瘍の治療において、腫瘍のワクチンのために、ウイルスの治療において 、特にレトロウイルスの感染、レンチウイルスの感染およびHIVの感染の治療 のために、ならびにマラリアの治療のためおよびマラリアの免疫化において、前 記活性化合物がアジュバントとして用いられることを特徴とする、請求項6〜1 4のいずれか1項に記載の使用。 16.前記活性化合物が、鎌状赤血球貧血の治療のために用いられることを特徴 とする、請求項6〜15のいずれか1項に記載の使用。 17.前記活性化合物が、保存血液または赤血球を含む血液代用物の貯蔵寿命を 延ばすために用いられることを特徴とする、請求項6〜16のいずれか1項に記 載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19541284A DE19541284C2 (de) | 1995-11-06 | 1995-11-06 | Verfahren zur Immunmodulation |
DE19541284.2 | 1995-11-06 | ||
PCT/EP1996/004791 WO1997017084A1 (de) | 1995-11-06 | 1996-11-04 | Medikament, insbesondere zur modulation der immunantwort bei der bekämpfung von viren, tumoren, bakterien und parasiten |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000500124A true JP2000500124A (ja) | 2000-01-11 |
Family
ID=7776729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9517831A Pending JP2000500124A (ja) | 1995-11-06 | 1996-11-04 | ウイルス、腫瘍、細菌および寄生体の抑制において免疫応答を特に調節するための医薬 |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP0859628B9 (ja) |
JP (1) | JP2000500124A (ja) |
AT (1) | ATE245995T1 (ja) |
CA (1) | CA2236888C (ja) |
DE (2) | DE19541284C2 (ja) |
ES (1) | ES2205065T3 (ja) |
WO (1) | WO1997017084A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524681A (ja) * | 2003-04-28 | 2006-11-02 | チルドレンズ ホスピタル メディカル センター | サポシンc−dops:新規抗腫瘍剤 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7262167B2 (en) | 1995-11-06 | 2007-08-28 | Exibona Ltd. | Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites |
DE19541284C2 (de) * | 1995-11-06 | 1998-09-24 | Kalden Joachim Robert Prof Dr | Verfahren zur Immunmodulation |
AU750414B2 (en) | 1998-07-13 | 2002-07-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
EP1520588B1 (en) | 1998-07-13 | 2014-12-24 | Board Of Regents, The University Of Texas System | Uses of antibodies to aminophospholipids for cancer treatment |
EP2311490A3 (en) | 1998-07-13 | 2011-05-04 | Board of Regents, The University of Texas System | Uses of antibodies to aminophospholipids for cancer treatment |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
AU771566B2 (en) * | 1999-06-09 | 2004-03-25 | I.D.M. Immuno-Designed Molecules | New molecular complexes presenting high affinity binding with respect to monocyte derived cells and their uses in therapy |
US7645739B2 (en) | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
ATE359807T1 (de) | 2001-02-21 | 2007-05-15 | Surromed Inc | Modifizierte annexin-proteine und verhinderung und behandlung von thrombose |
US7635676B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
JP2004529922A (ja) * | 2001-04-03 | 2004-09-30 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 生体内における細胞死の画像化の方法 |
DE10145254A1 (de) * | 2001-09-13 | 2003-04-10 | November Ag Molekulare Medizin | Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort |
US6982154B2 (en) * | 2002-02-21 | 2006-01-03 | Surromed, Inc. | Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
WO2004013303A2 (en) * | 2002-08-02 | 2004-02-12 | Surromed, Inc. | Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
DE10302422A1 (de) * | 2003-01-21 | 2004-07-29 | Responsif Gmbh | Medikament und Verwendung zur Tumortherapie |
WO2005027965A1 (en) * | 2003-09-24 | 2005-03-31 | Peter Krammer | Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
DE102004046540A1 (de) * | 2004-09-21 | 2006-04-06 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Annexin-Modulation und Infektionsresistenz |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0605561A4 (en) * | 1991-09-23 | 1995-04-12 | Gen Hospital Corp | APPENDIX XI. |
US5314992A (en) * | 1991-11-25 | 1994-05-24 | Trustees Of Dartmouth College | Lipocortin-1 receptor protein and its uses |
DE19541284C2 (de) * | 1995-11-06 | 1998-09-24 | Kalden Joachim Robert Prof Dr | Verfahren zur Immunmodulation |
-
1995
- 1995-11-06 DE DE19541284A patent/DE19541284C2/de not_active Expired - Fee Related
-
1996
- 1996-11-04 AT AT96938062T patent/ATE245995T1/de not_active IP Right Cessation
- 1996-11-04 WO PCT/EP1996/004791 patent/WO1997017084A1/de active IP Right Grant
- 1996-11-04 JP JP9517831A patent/JP2000500124A/ja active Pending
- 1996-11-04 EP EP96938062A patent/EP0859628B9/de not_active Expired - Lifetime
- 1996-11-04 CA CA002236888A patent/CA2236888C/en not_active Expired - Fee Related
- 1996-11-04 DE DE59610633T patent/DE59610633D1/de not_active Expired - Lifetime
- 1996-11-04 ES ES96938062T patent/ES2205065T3/es not_active Expired - Lifetime
- 1996-11-04 EP EP03017188A patent/EP1356818A3/de not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524681A (ja) * | 2003-04-28 | 2006-11-02 | チルドレンズ ホスピタル メディカル センター | サポシンc−dops:新規抗腫瘍剤 |
JP4762132B2 (ja) * | 2003-04-28 | 2011-08-31 | チルドレンズ ホスピタル メディカル センター | サポシンc−dops:新規抗腫瘍剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1356818A3 (de) | 2003-12-10 |
ATE245995T1 (de) | 2003-08-15 |
EP0859628B1 (de) | 2003-07-30 |
EP0859628A1 (de) | 1998-08-26 |
ES2205065T3 (es) | 2004-05-01 |
DE19541284C2 (de) | 1998-09-24 |
EP1356818A2 (de) | 2003-10-29 |
DE59610633D1 (de) | 2003-09-04 |
CA2236888C (en) | 2009-10-13 |
CA2236888A1 (en) | 1997-05-15 |
EP0859628B9 (de) | 2004-03-03 |
DE19541284A1 (de) | 1996-05-30 |
WO1997017084A1 (de) | 1997-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000500124A (ja) | ウイルス、腫瘍、細菌および寄生体の抑制において免疫応答を特に調節するための医薬 | |
US5601818A (en) | Cancer therapy utilizing malignant cells expressing HSV-TK | |
US20110195068A1 (en) | Pd-1 antagonists and methods of use thereof | |
Bridle et al. | Privileged antigen presentation in splenic B cell follicles maximizes T cell responses in prime-boost vaccination | |
JP2006523227A (ja) | Mda−7を含む方法および組成物 | |
JPH10501693A (ja) | リンパ球仲介型免疫応答を抑制するためのfasリガンドの使用 | |
JP2005533000A (ja) | Mda−7に関与する免疫誘導を増強する方法 | |
US20100166781A1 (en) | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity | |
JPH10505339A (ja) | 腫瘍疾患の治療のための生ワクチン | |
Diedrichs-Möhring et al. | A new small molecule for treating inflammation and chorioretinal neovascularization in relapsing-remitting and chronic experimental autoimmune uveitis | |
JP6186572B2 (ja) | 薬剤徐放担体及び薬剤徐放方法 | |
US20060153805A1 (en) | Viral vectors and the use of the same for gene therapy | |
JP2001517208A (ja) | 損傷した細胞ペプチドプロセッシングに関連する、例えばb7−1遺伝子で形質転換したrma−s細胞上に発現される抗原またはエピトープの治療的応用 | |
Burg et al. | Strategies for immunointerventions in dermatology | |
TR201807891T4 (tr) | Fibroz ve karaciğer hastalıklarının tedavi edilmesi. | |
AU2009200996B2 (en) | Method for growing human organs, treating diseases, and increasing longevity | |
US7125957B1 (en) | VPR mutant protein and its encoding gene having apoptosis-inducing action | |
JP2001089389A (ja) | 抗原特異的t細胞の誘導剤 | |
EA022915B1 (ru) | Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома | |
US20060171988A1 (en) | Method of treatment using foams as artificial lymph nodes | |
Weß et al. | Immuno-Oncology—The Translational Runway for Gene Therapy: Gene Therapeutics to Address Multiple Immune Targets | |
CN116585315A (zh) | 用于调节pd-1信号转导的组合物 | |
JPH05504761A (ja) | 哺乳類のhiv感染症の治療のための方法及び組成物 | |
JP2020517580A (ja) | 電離放射線耐性腫瘍を治療するための方法及び組成物 | |
RU2203071C2 (ru) | Применение белков в качестве антиретровирусных агентов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050124 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050425 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050628 |